000 05562nam a2200889 a 4500
001 vtls000079397
003 MTX
006 m eo d
007 cr cn |||m|||a
008 160715s2012 nyua foab 000 0 eng d
020 _a9781606504086 (electronic bk.)
020 _a9781606504222 (electronic bk.)
020 _z9780791860038 (print)
020 _z0791860035 (print)
035 _a(OCoLC)811139143
035 _a(CaPaEBR)10605115
035 _a(CaBNvSL)swl00401402
037 _a860038
_bASME
039 9 _a201607151144
_bstaff
_y201605041227
_zadmin
040 _aCaBNVSL
_cCaBNVSL
_dCaBNVSL
050 4 _aR857.N34
_bN253 2012
060 4 _aQT 36.5
_bN253 2012
082 0 4 _a610.284
_223
099 _aEbook
245 0 0 _aNanoparticles and brain tumor treatment
_h[electronic resource] /
_cGerardo Caruso ... [et al.].
260 _aNew York, N.Y. :
_bASME ;
_a[New York, N.Y.] (222 East 46th Street, New York, NY 10017) :
_bMomentum Press,
_c2012.
300 _a1 electronic text (viii, 99 p.) :
_bill., digital file.
490 1 _aBiomedical and nanomedical technologies
504 _aIncludes bibliographical references (p. [81]-99).
505 0 _a1. Introduction --
505 8 _a2. Glioma biology -- 2.1 Invasion and angiogenesis --
505 8 _a3. Blood-brain barrier -- 3.1 Blood-brain barrier physiology -- 3.2 Blood-brain barrier transport systems --
505 8 _a4. Nanomedicine and nanotechnology -- 4.1 Nanoparticle drug delivery -- 4.1.1 Nanoparticle distribution -- 4.1.2 Nanoparticle functionalization -- 4.1.3 Nanoparticle targeting -- 4.2 Nanomedicine and cancer -- 4.3 Nanomedicine and toxicity --
505 8 _a5. Nanoparticle technologies -- 5.1 Polymeric and polymer-drug conjugate nanoparticles -- 5.2 Micelle nanoparticles -- 5.3 Liposomes -- 5.4 Gold and silver nanoparticles -- 5.5 Metal oxide -- 5.6 Magnetic nanoparticles -- 5.7 Carbon nanotubes -- 5.8 Fullerenes -- 5.9 Peptides nanoparticles -- 5.10 Silica nanoparticles -- 5.11 Quantum dots -- 5.12 Dendrimers --
505 8 _a6. Nanomedicine applications in brain tumors -- 6.1 Brain tumor drug targeting -- 6.1.1 Systemic approaches -- 6.1.2 Physiological approaches -- 6.1.2.1 Receptor-mediated transcytosis -- 6.1.2.2 Adsorptive-mediated transcytosis -- 6.1.2.3 Efflux pump inhibition -- 6.1.2.4 Cell-mediated drug transport -- 6.1.3 Direct CNS approaches -- 6.1.3.1 Intracerebral routes -- 6.1.4 Drug modifications and prodrugs --
505 8 _a7. Experimental studies --
505 8 _a8. Conclusions -- References.
506 _aRestricted to libraries which purchase an unrestricted PDF download via an IP.
520 3 _aDespite progresses in surgery, radiotherapy, and in chemotherapy, an effective curative treatment of gliomas does not yet exist. Mortality is still close to 100% and the average survival of patients with GBM is less than 1 year. The efficacy of current anti-cancer strategies in brain tumors is limited by the lack of specific therapies against malignant cells. Besides, the delivery of the drugs to brain tumors is limited by the presence of the blood brain barrier. The oncogenesis of gliomas is characterized by several biological processes and genetic alterations, involved in the neoplastic transformation. The modulation of gene expression to more levels, such as DNA, mRNA, proteins and transduction signal pathways, may be the most effective modality to down-regulate or silence some specific gene functions. Gliomas are characterized by extensive microvascular proliferation and a higher degree of vasculature. In malignant gliomas targeted therapies efficacy is low. In this complex field, it seems to be very important to improve specific selective drugs delivery systems. Drugs, antisense oligonucleotides, small interference RNAs, engineered monoclonal antibodies and other therapeutic molecules may diffuse into CNS overcoming the BBB. Nanotechnology could be used both to improve the treatment efficacy and to reduce the adverse side effects.
530 _aAlso available in print.
538 _aMode of access: World Wide Web.
538 _aSystem requirements: Adobe Acrobat reader.
588 _aTitle from PDF t.p. (viewed on September 26, 2012).
650 0 _aNanomedicine.
_9115923
650 0 _aNanoparticles.
_9115924
650 0 _aBrain
_xTumors
_xTreatment.
_9115925
650 2 _aNanomedicine.
_9115923
650 2 _aNanoparticles.
_9115924
650 2 _aBrain Neoplasms
_xtherapy.
_9115926
653 _aNanomedicine
653 _aNanotechnology
653 _aNanoparticles
653 _aNanoparticles in Brain Tumor Treatment
653 _aNanoparticle Drug Delivery
653 _aNanoparticle Targeting
653 _aBlood-Brain Barrier
653 _aGlioma
653 _aAstrocytoma
653 _aGlioblastoma
653 _aBrain Tumor
653 _aGlioma Treatment
653 _aBrain Tumor Drug Targeting
653 _aAngiogenesis
653 _aPolymeric
653 _aNanoparticles and Brain Tumors
653 _aCarbon Nanotubes and Brain Tumors
653 _aFullerenes and Brain Tumors
653 _aSilica Nanoparticles and Brain Tumors
653 _aMicelle Nanoparticles and Brain Tumors
653 _aLiposome and Brain Tumors
700 1 _aCaruso, Gerardo.
_9115927
776 0 8 _iPrint version:
_z0791860035
_z9780791860038
830 0 _aBiomedical and nanomedical technologies.
_9115928
856 4 0 _uhttp://portal.igpublish.com/iglibrary/search/MPB0000052.html
942 _c10
999 _c75946
_d75946